Control of catecholamine-induced tachycardia with alinidine in the anesthetized dog.
Sinus tachycardia is a common complication of beta-adrenergic agonist therapy. A new selective bradycardic agent, N-allyl-clonidine, or alinidine, has been found effective against sinus tachycardia caused by a variety of stimuli. To determine whether it would also control catecholamine-induced sinus tachycardia, the effects of alinidine in two groups of anesthetized dogs treated with either dobutamine, 10 microg/ kg/min, or isoproterenol, 0.1 microg/kg/min, were studied. In both groups, alinidine significantly reduced the heart rate (P < .0001 in the dobutamine group, and P < .005 in the isoproterenol-infused dogs). The other hemodynamic effects of dobutamine were not adversely affected by alinidine, while the isoproterenol-infused dogs had a further afterload reduction when treated with alinidine. It is concluded that alinidine is effective against catecholamine-induced sinus tachycardia, possibly through mechanisms not related to beta-adrenergic receptors.
Benjamin
E
E
Department of Anesthesiology, Mount Sinai Hospital, One Gustave L. Levy Pl., New York, NY 10029, USA.
Paluch
T A
TA
Berger
S R
SR
Plawker
M
M
Kaplan
J A
JA
Iberti
T J
TJ
D000318:Adrenergic beta-Agonists / Q000009:adverse effects; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D003000:Clonidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004280:Dobutamine / Q000009:adverse effects; D004285:Dogs; D006339:Heart Rate / Q000187:drug effects; D007545:Isoproterenol / Q000009:adverse effects; D013616:Tachycardia, Sinus / Q000139:chemically induced / Q000188:drug therapy*
D000318:Adrenergic beta-Agonists; D000889:Anti-Arrhythmia Agents; D004280:Dobutamine; C022192:alinidine; D007545:Isoproterenol; D003000:Clonidine